Precision Drilling (PDS) Reaches $3.27 After 8.00% Down Move; Sorrento Therapeutics Has 0.67 Sentiment

February 15, 2018 - By Michael Collier

The stock of Precision Drilling Corporation (NYSE:PDS) is a huge mover today! The stock decreased 4.39% or $0.15 during the last trading session, reaching $3.27. About 1.88 million shares traded. Precision Drilling Corporation (NYSE:PDS) has declined 14.25% since February 15, 2017 and is downtrending. It has underperformed by 30.95% the S&P500.The move comes after 8 months negative chart setup for the $958.89 million company. It was reported on Feb, 15 by Barchart.com. We have $3.01 PT which if reached, will make NYSE:PDS worth $76.71 million less.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $769.05 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It currently has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.

Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The company has market cap of $958.89 million. The firm operates in two divisions, Contract Drilling Services, and Completion and Production Services. It currently has negative earnings. The Contract Drilling Services segment offers onshore well drilling services to exploration and production companies in the oil and natural gas industry.

Among 19 analysts covering Precision Drilling Corporation (NYSE:PDS), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Precision Drilling Corporation had 52 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating by Scotia Capital given on Friday, October 9. The firm earned “Buy” rating on Thursday, September 14 by Cowen & Co. The stock of Precision Drilling Corporation (NYSE:PDS) earned “Outperform” rating by Raymond James on Wednesday, April 26. Jefferies maintained Precision Drilling Corporation (NYSE:PDS) rating on Thursday, July 20. Jefferies has “Buy” rating and $600 target. Jefferies maintained the stock with “Buy” rating in Wednesday, August 2 report. Cowen & Co maintained Precision Drilling Corporation (NYSE:PDS) on Tuesday, February 16 with “Outperform” rating. On Tuesday, September 12 the stock rating was downgraded by JP Morgan to “Neutral”. Jefferies maintained it with “Buy” rating and $4.5 target in Wednesday, September 6 report. The firm has “Buy” rating by Raymond James given on Thursday, July 6. The stock of Precision Drilling Corporation (NYSE:PDS) has “Equal-Weight” rating given on Wednesday, June 21 by Morgan Stanley.

Wildcat Capital Management Llc holds 0.85% of its portfolio in Sorrento Therapeutics, Inc. for 2.80 million shares. Gagnon Securities Llc owns 31,586 shares or 0.02% of their US portfolio. Moreover, Matrix Asset Advisors Inc Ny has 0.02% invested in the company for 72,000 shares. The New York-based A.R.T. Advisors Llc has invested 0.01% in the stock. Crow Point Partners Llc, a Massachusetts-based fund reported 44,565 shares.

The stock increased 12.73% or $1.05 during the last trading session, reaching $9.3. About 3.65M shares traded or 70.66% up from the average. Sorrento Therapeutics, Inc. (SRNE) has declined 73.31% since February 15, 2017 and is downtrending. It has underperformed by 90.01% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>